Unknown PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT02422199

A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab

Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Conditions HER2 Positive Metastatic Breast Cancer

Interventions Lapatinib capecitabine pyrotinib

Updated 7 times since 2017 Last updated: Jul 5, 2018 Started: May 31, 2015 Primary completion: Oct 31, 2016 Completion: Dec 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02422199, this PHASE1/PHASE2 trial focuses on HER2 Positive Metastatic Breast Cancer and remains ongoing. Sponsored by Jiangsu HengRui Medicine Co., Ltd., it has been updated 7 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
Aug 2020 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2

Status: Active Not Recruiting → Unknown Status
Aug 2018 — Aug 2020 [monthly]

Active Not Recruiting PHASE1_PHASE2

▶ Show 2 earlier versions

Jun 2018 — Aug 2018 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1_PHASE2

First recorded

May 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangsu HengRui Medicine Co., Ltd.

Data source: Jiangsu HengRui Medicine Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China